Details for Patent: 12,377,071
Which drugs does patent 12,377,071 protect, and when does it expire?
Patent 12,377,071 protects VELSIPITY and is included in one NDA.
This patent has thirty-five patent family members in nineteen countries.
Summary for Patent: 12,377,071
| Title: | Methods of treating conditions related to the S1P1 receptor |
| Abstract: | Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta [b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of Compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne. |
| Inventor(s): | Alan GLICKLICH, Maria Matilde Sanchez KAM, William R. Shanahan |
| Assignee: | Arena Pharmaceuticals Inc |
| Application Number: | US18/406,732 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; Dosage form; |
Drugs Protected by US Patent 12,377,071
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | VELSIPITY | etrasimod arginine | TABLET;ORAL | 216956-001 | Oct 12, 2023 | RX | Yes | Yes | 12,377,071 | ⤷ Start Trial | A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING ESTRASIMOD L-ARGININE IN AN AMOUNT EQUIVALENT TO ABOUT 2.0 MG OF ESTRASIMOD | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,377,071
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2016205361 | ⤷ Start Trial | |||
| Australia | 2021200129 | ⤷ Start Trial | |||
| Australia | 2022283660 | ⤷ Start Trial | |||
| Canada | 3002540 | ⤷ Start Trial | |||
| China | 107405332 | ⤷ Start Trial | |||
| China | 116850181 | ⤷ Start Trial | |||
| Denmark | 3242666 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
